Ares Commercial cut once again. Q4-2024 saw negative distributable EPS and increased loans rated 4 and 5. ACRE has had the worst underwriting results in mortgage REITs, and it is not even close.

Apple: Still Too Expensive For My Liking

Chevron wants to save about $3 billion. Layoffs are on the horizon. — Negative
CVX Market Watch — February 12, 2025The integrated energy company said that layoffs will affect 15% to 20% of its employees, starting this year and with most layoffs completed before the end of 2026.

Zillow's Mixed Quarter: Analysts See Strong Execution But Caution On 2025 Guidance — Neutral
Z ZG Benzinga — February 12, 2025Zillow Group, Inc. ZG shares are trading lower after the company reported mixed results on Tuesday.

Official inflation numbers came out yesterday morning, showing an increase across the board. This has stoked fears the Fed may not decrease rates and may have to even increase rates in an already fragile environment.

Why Doximity (DOCS) Might be Well Poised for a Surge — Positive
DOCS Zacks Investment Research — February 12, 2025Doximity (DOCS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why InterDigital (IDCC) Might be Well Poised for a Surge — Positive
IDCC Zacks Investment Research — February 12, 2025InterDigital (IDCC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock — Positive
CSTL Zacks Investment Research — February 12, 2025Castle Biosciences (CSTL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Bank of America CEO: Rates are going to stay where they are — Neutral
BAC CNBC Television — February 12, 2025Bank of America CEO Brian Moynihan said Wednesday that strong consumer spending so far this year means that the Federal Reserve will probably hold off on cutting its benchmark interest rate.

Oatly (OTLY -14.49%) stock is sinking Wednesday following the release of its fourth-quarter results. The beverage specialist's share price was down 14.3% as of 12:30 p.m.

3 Stocks Plunging After Earnings, Options Traders Respond — Negative
LYFT VRT Z Schaeffers Research — February 12, 2025Earnings season can be a double-edged sword.

Micron (MU -2.15%) stock is losing ground in Wednesday trading. The company's share price was down 2.5% as of 1 p.m.

Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints — Neutral
BIIB Zacks Investment Research — February 12, 2025BIIB's Q4 earnings and sales beat estimates. EPS guidance for 2025 falls short of expectations.

Monarch Casino Q4 Earnings & Revenues Top, Adjusted EBITDA Up Y/Y — Neutral
MCRI Zacks Investment Research — February 12, 2025MCRI's fourth-quarter 2024 results reflect year-over-year growth across its top and bottom lines. Dive in to know the factors behind the stock's quarterly performance.

InvenTrust Properties Corp. (IVT) Q4 2024 Earnings Call Transcript — Neutral
IVT Seeking Alpha — February 12, 2025InvenTrust Properties Corp. (NYSE:IVT ) Q4 2024 Earnings Conference Call February 12, 2025 10:00 AM ET Company Participants Dan Lombardo - Vice President, Investor Relations DJ Busch - President & Chief Executive Officer Mike Phillips - Chief Financial Officer Christy David - Chief Operating Officer Dave Heimberger - Chief Investment Officer Conference Call Participants Dori Kesten - Wells Fargo Jeff Spector - Bank of America Linda Tsai - Jefferies Floris van Dijkum - Compass Point Paulina Rojas - Green Street Operator Thank you for standing by, and welcome to InvenTrust's Fourth Quarter and Full Year 2024 Earnings Conference Call. My …

Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN — Neutral
REGN Accesswire — February 12, 2025NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=129065&wire=1 or contact Joseph E. Levi, Esq.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Aspen Technology Inc. — Neutral
AZPN Accesswire — February 12, 2025NEW YORK, NY / ACCESS Newswire / February 12, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Aspen Technology Inc. ("AZPN" or the "Company") (NASDAQ:AZPN) stock purchased prior to January 27, 2025. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of Aspen Technology Inc. and Emerson Electric (EMR), whether the Board of AZPN have harmed stockholders by agreeing to enter into this transaction, and whether all material facts have been properly disclosed to stockholders.

HLIT ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Harmonic Inc. — Neutral
HLIT Accesswire — February 12, 2025NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmonic Inc. ("Harmonic Inc.") (NASDAQ:HLIT) concerning possible violations of federal securities laws. Harmonic reported its third quarter financial results on February 10, 2025.

Harmonic Inc. Being Investigated on Behalf of Harmonic Inc. Investors. Contact Levi & Korsinsky For Details — Neutral
HLIT Accesswire — February 12, 2025NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmonic Inc. ("Harmonic Inc.") (NASDAQ:HLIT) concerning possible violations of federal securities laws. Harmonic reported its third quarter financial results on February 10, 2025.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Revance Therapeutics Inc — Neutral
RVNC Accesswire — February 12, 2025NEW YORK, NY / ACCESS Newswire / February 12, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Revance Therapeutics Inc ("RVNC" or the "Company") (NASDAQ:RVNC) Stock purchased prior to August 11, 2024. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Revance by Crown Laboratories, Inc. ("Crown").
